Article
Shorter durations and lower doses of peginterferon alfa-2a are associated with inferior hepatitis B e antigen seroconversion rates in hepatitis B virus genotypes B or C.
Hepatology (Baltimore, Md.) - 1 Nov 2011
Liaw Y-F, Jia J-D, Chan H L Y, Han K H, Tanwandee T, Chuang W L, Tan D M, Chen X Y, Gane E, Piratvisuth T, Chen L, Xie Q, Sung J J Y, Wat C, Bernaards C, Cui Y, Marcellin P
Abstract excerpt
UNLABELLED: As there is currently a lack of consensus on the most appropriate dose and duration of peginterferon alfa-2a (PEG-IFNα-2a) therapy in hepatitis B e antigen (HBeAg)-positive patients, the efficacy and safety of either 24 or 48 weeks' duration and 90 μg/week or 180 μg/week doses were co...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
